WEBULL
News
SLRN
2.270
0.00%
0.00
*News On ACELYRIN Inc. (SLRN) Now Under ALMS
Dow Jones · 05/21 21:08
ACELYRIN Completes Merger and Delists from Nasdaq
TipRanks · 05/21 13:48
Alumis completes merger with Acelyrin
TipRanks · 05/21 13:15
ALUMIS INC - CEO STATES MERGER EXTENDS CASH RUNWAY INTO 2027
Reuters · 05/21 13:10
ACELYRIN Stockholders Approve Merger with Alumis
TipRanks · 05/19 20:55
Weekly Report: what happened at SLRN last week (0512-0516)?
Weekly Report · 05/19 09:11
Alumis price target lowered to $25 from $26 at Oppenheimer
TipRanks · 05/15 11:35
Form 10-Q for the quarterly period ended March 31, 2025
Press release · 05/14 20:24
ACELYRIN Stockholders Approve Merger With Alumis, Securing 0.4814 Shares Per ACELYRIN Share At Closing
Benzinga · 05/13 17:07
Lumis Stockholders Approve All Proposals Required To Be Approved In Connection With Pending Merger With ACELYRIN; Merger Is Expected To Close In Q2 2025
Benzinga · 05/13 17:03
ALUMIS INC - MERGER EXPECTED TO CLOSE IN Q2 2025
Reuters · 05/13 17:00
Press Release: ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Dow Jones · 05/13 17:00
Weekly Report: what happened at SLRN last week (0505-0509)?
Weekly Report · 05/12 09:11
WEX, Acelyrin, and More Stocks See Action From Activist Investors
Barron‘s · 05/09 22:18
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
Barchart · 05/06 15:30
Weekly Report: what happened at SLRN last week (0428-0502)?
Weekly Report · 05/05 09:11
Acelyrin urges stockholders to vote for proposed merger with Alumis
TipRanks · 05/01 17:45
Press Release: ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Dow Jones · 05/01 17:30
Press Release: ACELYRIN Reiterates Benefits of -2-
Dow Jones · 05/01 17:30
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Barchart · 05/01 12:30
More
Webull provides a variety of real-time SLRN stock news. You can receive the latest news about Acelyrin through multiple platforms. This information may help you make smarter investment decisions.
About SLRN
ACELYRIN, INC. is a late-stage clinical biopharma company. The Company is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The Company has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The Company is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.